VH4127 (TFA)
VH4127 TFA is a cyclic peptide targeting the low density lipoprotein receptor (LDLR) with a KD of 18 nM for hLDLR. VH4127 TFA specifically binds to rodent and human epidermal growth factor (EGF) homology domain of LDLR[1][2].
Product Specifications
UNSPSC
12352209
Target
LDLR
Related Pathways
Metabolic Enzyme/Protease
Field of Research
Metabolic Disease
Purity
98.67
Smiles
O=C(N[C@@H](CC(C)C)C(N[C@@H](CCCNC(N)=N)C(NCC(N[C@H](C(SSC[C@@H](NC(CC)=O)C(N[C@@H](CCSC)C(N1[C@H]2CSC1)=O)=O)(C)C)C(N)=O)=O)=O)=O)[C@H](CCCNC(N)=N)NC2=O.OC(C(F)(F)F)=O.[x]
Molecular Formula
C40H71N15O9S4.xC2HF3O2
Molecular Weight
1034.35 (free base)
References & Citations
[1]Xue Yang, et al. Preparation and In Vitro Validation of a Cucurbit[7]uril-Peptide Conjugate Targeting the LDL Receptor. J Med Chem. 2023 Jul 13;66 (13) :8844-8857.|[2]Angélina Acier, et al. LDL receptor-peptide conjugate as in vivo tool for specific targeting of pancreatic ductal adenocarcinoma. Commun Biol. 2021 Aug 19;4 (1) :987.
Shipping Conditions
Blue Ice
Storage Conditions
-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)
Scientific Category
Peptides
Clinical Information
No Development Reported
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
